Johnson & Johnson (JNJ) Free cash flow
- Free cash flow · 12 months (USD): Value $22.24B; Formula and calculation Operating cash flow minus capital spending; distinct from the saved levered FCF quote figure. Period ending 2026-06-28..
- Price / free cash flow · 12 months: Value (m); Formula and calculation Market cap / trailing-year free cash flow; inverse of FCF yield before percent scaling. Period ending 2026-06-28..
- Free cash flow yield · 12 months: Value (m); Formula and calculation (Operating cash flow − capital spending) / current market cap. Period ending 2026-06-28..
- Free cash flow margin · 12 months: Value 22.71%; Formula and calculation (Operating cash flow − capital spending) / revenue. Period ending 2026-06-28..
Free cash flow
Overview →Financial period ending 2026-06-28; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Free cash flow · 12 months (USD) | $22.24B | Operating cash flow minus capital spending; distinct from the saved levered FCF quote figure. Period ending 2026-06-28. $27.61B − $5.36B ≈ $22.24B |
| Price / free cash flow · 12 months | (m) | Market cap / trailing-year free cash flow; inverse of FCF yield before percent scaling. Period ending 2026-06-28. Calculation unavailable: missing inputs remain (m). |
| Free cash flow yield · 12 months | (m) | (Operating cash flow − capital spending) / current market cap. Period ending 2026-06-28. Calculation unavailable: missing inputs remain (m). |
| Free cash flow margin · 12 months | 22.71% | (Operating cash flow − capital spending) / revenue. Period ending 2026-06-28. $22.24B ÷ $97.93B × 100 ≈ 22.71% |
| Free cash flow per share · 12 months | (m) | (Trailing-year operating cash flow − capital spending) / reported quarter-end common shares. Period ending 2026-06-28. Calculation unavailable: missing inputs remain (m). |
| Operating cash flow · 12 months | $27.61B | Cash generated by operating activities. Period ending 2026-06-28. |
| Operating cash flow / net income · 12 months | 1.31× | Operating cash flow / net income. Period ending 2026-06-28. $27.61B ÷ $21.04B ≈ 1.31× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating cash flow | 27.61B USD | Net Cash Provided by (Used in) Operating Activities |
| Capital spending | 5.36B USD | Payments to Acquire Property, Plant, and Equipment |
| Market cap | (m) | |
| Free cash flow | 22.24B USD | Net Cash Provided by (Used in) Operating Activities · Payments to Acquire Property, Plant, and Equipment |
| Revenue | 97.93B USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Quarter-end shares | (m) | |
| Net income | 21.04B USD | Net Income (Loss) Attributable to Parent |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Free cash flow | FCF per share | Operating cash flow | Capital spending (USD) | Market cap (USD) | Revenue (USD) | Quarter-end shares (shares) | Net income (USD) | Price / FCF | FCF yield | FCF margin | Cash conversion |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-28 | $22.24B | (m) | $27.61B | $5.36B | (m) | $97.93B | (m) | $21.04B | (m) | (m) | 22.71% | 1.31× |
| 2026-03-29 | $17.78B | (m) | $22.87B | $5.09B | (m) | $96.36B | (m) | $21.04B | (m) | (m) | 18.46% | 1.09× |
| 2025-12-28 | $19.70B | (m) | $24.53B | $4.83B | (m) | $94.19B | (m) | $26.80B | (m) | (m) | 20.91% | 0.92× |
| 2025-09-28 | $19.60B | (m) | $24.20B | $4.61B | (m) | $92.15B | (m) | $25.12B | (m) | (m) | 21.27% | 0.96× |
| 2025-06-29 | $18.55B | (m) | $23.03B | $4.48B | (m) | $90.63B | (m) | $22.66B | (m) | (m) | 20.47% | 1.02× |
| 2025-03-30 | $20.37B | (m) | $24.78B | $4.41B | (m) | $89.33B | (m) | $21.81B | (m) | (m) | 22.80% | 1.14× |
| 2024-12-29 | $19.84B | (m) | $24.27B | $4.42B | (m) | $88.82B | (m) | $14.07B | (m) | (m) | 22.34% | 1.73× |
| 2024-09-29 | $20.75B | (m) | $25.15B | $4.40B | (m) | $87.70B | (m) | $14.68B | (m) | (m) | 23.66% | 1.71× |
| 2024-06-30 | $20.30B | (m) | $24.64B | $4.34B | (m) | $86.58B | (m) | $38.02B | (m) | (m) | 23.45% | 0.65× |
| 2024-03-31 | $18.70B | (m) | $23.19B | $4.49B | (m) | $85.65B | (m) | $38.48B | (m) | (m) | 21.84% | 0.60× |
| 2023-12-31 | $18.25B | (m) | $22.79B | $4.54B | (m) | $85.16B | (m) | $35.15B | (m) | (m) | 21.43% | 0.65× |
| 2023-10-01 | $15.74B | (m) | $20.28B | $4.54B | (m) | $98.66B | (m) | $34.62B | (m) | (m) | 15.95% | 0.59× |
| 2023-07-02 | $14.55B | (m) | $19.07B | $4.53B | (m) | $97.77B | (m) | $13.05B | (m) | (m) | 14.88% | 1.46× |
| 2023-04-02 | $16.21B | (m) | $20.47B | $4.26B | (m) | $96.26B | (m) | $12.72B | (m) | (m) | 16.84% | 1.61× |
| 2023-01-01 | $17.18B | (m) | $21.19B | $4.01B | (m) | $94.94B | (m) | $17.94B | (m) | (m) | 18.10% | 1.18× |
| 2022-10-02 | $17.74B | (m) | $21.58B | $3.84B | (m) | $96.04B | (m) | $19.16B | (m) | (m) | 18.47% | 1.13× |
| 2022-07-03 | $19.95B | (m) | $23.58B | $3.63B | (m) | $95.59B | (m) | $18.37B | (m) | (m) | 20.87% | 1.28× |
| 2022-04-03 | $19.73B | (m) | $23.32B | $3.58B | (m) | $94.88B | (m) | $19.83B | (m) | (m) | 20.80% | 1.18× |
| 2022-01-02 | $19.76B | (m) | $23.41B | $3.65B | (m) | $93.78B | (m) | $20.88B | (m) | (m) | 21.07% | 1.12× |
| 2021-10-03 | $22.46B | (m) | $26.02B | $3.56B | (m) | $91.45B | (m) | $17.88B | (m) | (m) | 24.56% | 1.46× |
| 2021-07-04 | $22.56B | (m) | $26.11B | $3.55B | (m) | $89.19B | (m) | $17.77B | (m) | (m) | 25.30% | 1.47× |
| 2021-04-04 | $20.85B | (m) | $24.25B | $3.40B | (m) | $84.21B | (m) | $15.12B | (m) | (m) | 24.76% | 1.60× |
| 2021-01-03 | $20.19B | (m) | $23.54B | $3.35B | (m) | $82.58B | (m) | $14.71B | (m) | (m) | 24.45% | 1.60× |
| 2020-09-27 | $18.31B | (m) | $21.59B | $3.28B | (m) | $80.86B | (m) | $16.99B | (m) | (m) | 22.64% | 1.27× |
| 2020-06-28 | $17.44B | (m) | $20.73B | $3.29B | (m) | $80.50B | (m) | $15.19B | (m) | (m) | 21.67% | 1.37× |
| 2020-03-29 | $19.76B | (m) | $23.23B | $3.47B | (m) | $82.73B | (m) | $17.17B | (m) | (m) | 23.89% | 1.35× |
| 2019-12-29 | $19.92B | (m) | $23.42B | $3.50B | (m) | $82.06B | (m) | $15.12B | (m) | (m) | 24.27% | 1.55× |
| 2019-09-29 | $19.71B | (m) | $23.26B | $3.56B | (m) | $81.71B | (m) | $14.15B | (m) | (m) | 24.12% | 1.64× |
| 2019-06-30 | $18.38B | (m) | $22.01B | $3.63B | (m) | $81.33B | (m) | $16.33B | (m) | (m) | 22.60% | 1.35× |
| 2019-03-31 | $18.47B | (m) | $22.14B | $3.67B | (m) | $81.59B | (m) | $14.68B | (m) | (m) | 22.64% | 1.51× |
| 2018-12-30 | $18.53B | (m) | $22.20B | $3.67B | (m) | $81.58B | (m) | $15.30B | (m) | (m) | 22.71% | 1.45× |
| 2018-09-30 | $18.47B | (m) | $22.06B | $3.59B | (m) | (m) | (m) | $1.54B | (m) | (m) | (m) | 14.31× |
| 2018-07-01 | $18.49B | (m) | $22.06B | $3.56B | (m) | (m) | (m) | $1.37B | (m) | (m) | (m) | 16.08× |
| 2018-04-01 | $18.37B | (m) | $21.75B | $3.38B | (m) | (m) | (m) | $1.25B | (m) | (m) | (m) | 17.47× |
| 2017-12-31 | $17.78B | (m) | $21.06B | $3.28B | (m) | (m) | (m) | $1.30B | (m) | (m) | (m) | 16.20× |
| 2017-10-01 | $18.47B | (m) | $21.60B | $3.13B | (m) | (m) | (m) | $15.83B | (m) | (m) | (m) | 1.37× |
| 2017-07-02 | $17.62B | (m) | $20.70B | $3.08B | (m) | (m) | (m) | $16.34B | (m) | (m) | (m) | 1.27× |
| 2017-04-02 | $16.34B | (m) | $19.49B | $3.15B | (m) | (m) | (m) | $16.50B | (m) | (m) | (m) | 1.18× |
| 2017-01-01 | $15.54B | (m) | $18.77B | $3.23B | (m) | (m) | (m) | $16.54B | (m) | (m) | (m) | 1.13× |
| 2016-10-02 | $13.41B | (m) | $16.91B | $3.50B | (m) | (m) | (m) | $15.94B | (m) | (m) | (m) | 1.06× |
| 2016-07-03 | $14.14B | (m) | $17.69B | $3.55B | (m) | (m) | (m) | $15.03B | (m) | (m) | (m) | 1.18× |
| 2016-04-03 | $14.61B | (m) | $18.17B | $3.56B | (m) | (m) | (m) | $15.38B | (m) | (m) | (m) | 1.18× |
| 2016-01-03 | $15.82B | (m) | $19.28B | $3.46B | (m) | (m) | (m) | $15.41B | (m) | (m) | (m) | 1.25× |
| 2015-09-27 | $14.97B | (m) | $18.56B | $3.59B | (m) | (m) | (m) | $14.71B | (m) | (m) | (m) | 1.26× |
| 2015-06-28 | $13.54B | (m) | $17.09B | $3.56B | (m) | (m) | (m) | $16.11B | (m) | (m) | (m) | 1.06× |
| 2015-03-29 | $13.79B | (m) | $17.42B | $3.63B | (m) | (m) | (m) | $15.92B | (m) | (m) | (m) | 1.09× |
| 2014-12-28 | $14.76B | (m) | $18.47B | $3.71B | (m) | (m) | (m) | $16.32B | (m) | (m) | (m) | 1.13× |
| 2014-09-28 | $14.60B | (m) | $18.25B | $3.65B | (m) | (m) | (m) | $17.32B | (m) | (m) | (m) | 1.05× |
| 2014-06-29 | $15.83B | (m) | $19.54B | $3.71B | (m) | (m) | (m) | $15.55B | (m) | (m) | (m) | 1.26× |
| 2014-03-30 | $15.42B | (m) | $19.06B | $3.64B | (m) | (m) | (m) | $15.06B | (m) | (m) | (m) | 1.27× |
| 2013-12-29 | $13.82B | (m) | $17.41B | $3.60B | (m) | (m) | (m) | $13.83B | (m) | (m) | (m) | 1.26× |
| 2013-09-29 | $13.33B | (m) | $16.65B | $3.32B | (m) | (m) | (m) | $12.88B | (m) | (m) | (m) | 1.29× |
| 2013-06-30 | $12.49B | (m) | $15.68B | $3.19B | (m) | (m) | (m) | $12.87B | (m) | (m) | (m) | 1.22× |
| 2013-03-31 | $11.86B | (m) | $14.88B | $3.02B | (m) | (m) | (m) | $10.44B | (m) | (m) | (m) | 1.43× |
| 2012-12-30 | $12.46B | (m) | $15.40B | $2.93B | (m) | (m) | (m) | $10.85B | (m) | (m) | (m) | 1.42× |
| 2012-09-30 | $12.56B | (m) | $15.47B | $2.91B | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2012-07-01 | $12.66B | (m) | $15.60B | $2.94B | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2012-04-01 | $11.82B | (m) | $14.78B | $2.96B | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2012-01-01 | $11.40B | (m) | $14.30B | $2.89B | (m) | (m) | (m) | $9.67B | (m) | (m) | (m) | 1.48× |
| 2011-10-02 | $11.95B | (m) | $14.67B | $2.72B | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-07-03 | $12.54B | (m) | $15.08B | $2.54B | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-04-03 | $12.59B | (m) | $15.01B | $2.42B | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-01-02 | $14.00B | (m) | $16.39B | $2.38B | (m) | (m) | (m) | $13.33B | (m) | (m) | (m) | 1.23× |
| 2010-10-03 | $15.58B | (m) | $17.85B | $2.27B | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-07-04 | $15.65B | (m) | $17.91B | $2.26B | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-04-04 | $15.11B | (m) | $17.43B | $2.33B | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-01-03 | $14.21B | (m) | $16.57B | $2.37B | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2009-09-27 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2009-06-28 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2009-03-29 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2008-12-28 | $11.91B | (m) | $14.97B | $3.07B | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2008-09-28 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2008-06-29 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2007-12-30 | $12.08B | (m) | $15.02B | $2.94B | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| Merck & Co., Inc. (MRK) | United States | $365.215B | 99.96 |
| ELI LILLY & Co (LLY) | United States | $1,113.804B | 42.28 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |